Article and Video CATEGORIES
The trial of the insulin-like growth factor-1 receptor (IGF-1R) inhibitor figitumumab in combination with carbo/taxol as first line therapy for advanced NSCLC was officially closed after it was determined that the experimental arm would not have a meaningful chance of appearing superior to standard carbo/taxol with a placebo ("futility analysis"). Dr. Sanborn had previously written about this trial after it was put on hold due to safety concerns with this combination.
Importantly, this agent is still being studied in combination with Tarceva, and that trial is still ongoing, as are trials with this agent in other cancers. It's not clear whether the safety concerns figitumumab in combination with chemo are specific to this one agent or whether other agents that inhibit the new target IGF-1R as a potentially important anti-cancer treatment will also show show safety problems and lack of efficacy in combination with chemo, nor do we know whether the issues are specific to carbo/taxol or could be a problem with other chemotherapy combinations.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…